Phase I/II study: on the toxicity and effects of combining the p53 synthetic long peptides vaccine with either Imiquimod or Interferon-alfa to induce polarized p53-specific immunity in patients treated for colorectal cancer.

Trial Profile

Phase I/II study: on the toxicity and effects of combining the p53 synthetic long peptides vaccine with either Imiquimod or Interferon-alfa to induce polarized p53-specific immunity in patients treated for colorectal cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2012

At a glance

  • Drugs Imiquimod (Primary) ; ISA 102 (Primary) ; Peginterferon alfa-2b (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 06 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top